Highlights

  • FY26 Revenue reached USD 60.9 million, compared with USD 53.1 million for FY25.
  • FY26 clinical-trials revenue was USD 58.4 million, while healthcare revenue was USD 2.5 million.
  • The company reported USD 89.0 million of new net sales contracts in FY26.
  • Contracted future revenue was USD 118.5 million entering FY27.

Cogstate Limited (ASX:CGS) provides digital cognitive assessments for clinical research and healthcare use. Its shares closed at AUD 3.355 on 2 November 2026. Recent 2026 company disclosures cover financial performance, operating developments and the work ahead. The relevant Business measures vary with its products, customers and funding model.

Cognitive Testing Across Drug Development

Cogstate Limited (ASX:CGS) provides technology-enabled cognitive assessments used in Clinical Trials and healthcare. Pharmaceutical and biotechnology customers use its tests to measure cognitive function during development of treatments for central nervous system conditions. The company reports clinical trials and healthcare activities separately, reflecting differences in customer use and revenue contribution. Its work involves test delivery, data collection and analysis across research programs. The principal commercial exposure remains sponsor spending on clinical trials, which can vary with individual development programs, their recruitment timetables and funding decisions.

FY26 Contracts and Product Activity

In August 2026, Cogstate Limited (ASX:CGS) released its FY26 annual report, documenting USD 89.0 million in new net sales contracts compared with USD 41.3 million in FY25. The contracted future revenue balance rose to USD 118.5 million from USD 90.0 million. In an October 2026 AGM presentation, management said USD 48.3 million of that contracted balance was expected to be recognised in FY27 as of 1 July 2026. Contracted work offers visibility, but timing of revenue recognition depends on sponsors progressing trials and completing agreed activities. The company also reported that 77% of FY26 contract value originated outside Alzheimer’s disease, reflecting its activity across other central nervous system indications.

Revenue, Earnings and Operating Cash Flow

Cogstate Limited (ASX:CGS) reported FY26 total revenue of USD 60.864 million, up from USD 53.091 million. EBITDA was USD 18.339 million against USD 15.959 million, and net profit after tax increased to USD 11.895 million from USD 10.145 million. Clinical trials contributed USD 58.367 million in revenue; healthcare generated USD 2.497 million. The FY26 clinical-trials contribution Margin was 57%, compared with 60% in FY25, making contract mix and delivery costs pertinent to future results. At its October AGM, the company stated FY26 Operating Cash Flow was USD 8.5 million and identified a higher receivables balance at year-end as a contributing factor. Cash collection is therefore distinct from accounting profit and remains worth monitoring.

Business Risks and Near-Term Monitoring

Cogstate Limited (ASX:CGS) operates in a specialised service market dependent on clinical research programs. Trial cancellations, postponed enrolment, slower contract conversion and sponsor concentration could affect both reported revenue and cash receipts. Technology-development spending, recruitment needs and execution across many simultaneous studies also affect costs. Although contracted future revenue provides a quantified pipeline of work, it is not equivalent to cash already collected. The next relevant disclosures include half-year revenue conversion, changes in the contracted order book, operating cash receipts and the contribution of different therapeutic areas. Monitoring both the percentage of revenue earned and the timing of customer payments will help distinguish operating performance from working-capital movements.

Key Insights

Cogstate Limited (ASX:CGS) ended FY26 with higher revenue, earnings and contracted future revenue. Clinical-trials services remained the main source of revenue, while the mix of therapeutic indications broadened. The key measurable issues are how contracted work converts into revenue, whether margins improve, and whether collection of receivables supports cash flow through FY27.